Agalsidase beta
Generic name: Agalsidase Beta
Brand names: Fabrazyme
Dosage form: intravenous powder for injection (35 mg; 5 mg)
Drug class:
Lysosomal enzymes
Usage of Agalsidase beta
Agalsidase beta is used in the treatment of Fabry disease (a deficiency of alpha-galactosidase A enzyme) in adults and children at least 2 years old.
Agalsidase beta may also be used for purposes other than those listed here.
Agalsidase beta side effects
Get emergency medical help if you have signs of an allergic reaction:
Some side effects may occur during the injection. Tell your caregiver right away if you have any of these signs of an infusion reaction:
Common side effects of agalsidase beta may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Agalsidase beta
Tell your doctor if you have ever had:
Tell your doctor if you are pregnant or breastfeeding.
Your name may be listed on a Fabry disease patient registry. This is to track the progress of your disease and to evaluate the treatment effects of agalsidase beta. Taking part in this registry is especially important if you are pregnant or breast-feeding.
Relate drugs
- Agalsidase beta
- Aldurazyme
- Alglucerase
- Alglucosidase alfa
- Avalglucosidase alfa
- Avalglucosidase alfa-ngpt
- Myozyme
- Brineura
- Ceredase
- Cerezyme
- Cerliponase alfa
- Elaprase
- Elelyso
- Elfabrio
- Elosulfase alfa
- Fabrazyme
- Galsulfase
- Idursulfase
- Imiglucerase
- Kanuma
- Lamzede
- Laronidase
- Lumizyme
- Mepsevii
- Naglazyme
- Nexviazyme
- Olipudase alfa
- Olipudase alfa-rpcp
- Pegunigalsidase alfa-iwxj
- Pombiliti
- Sebelipase alfa
- Taliglucerase alfa
- Velaglucerase alfa
- Velmanase alfa-tycv
- Vestronidase alfa
- Vestronidase alfa-vjbk
- Vimizim
- VPRIV
- Xenpozyme
How to use Agalsidase beta
Usual Adult Dose for Fabry Disease:
1 mg/kg via IV infusion every 2 weeksINFUSION RATE: Initial infusion rate should not exceed 0.25 mg/min (15 mg/hr); once tolerance to the infusion is well established, may increase infusion rate in increments of 0.05 to 0.08 mg/min with each subsequent infusionMaximum infusion rate (weight less than 30 kg): 0.25 mg/minuteMinimum infusion duration (weight 30 kg or greater): 1.5 hours (based on individual patient tolerability) Comments:-Antipyretics are recommended prior to infusions; anti-histamines should also be given in patients who have had an infusion-associated reaction.-For patients who have had a positive skin test, see dose adjustment section for rechallenge administration. Use: For treatment of patients with confirmed Fabry disease.
Usual Pediatric Dose for Fabry Disease:
2 years or older: 1 mg/kg via IV infusion every 2 weeksINFUSION RATE: Initial infusion rate should not exceed 0.25 mg/min (15 mg/hr); once tolerance to the infusion is well established, may increase infusion rate in increments of 0.05 to 0.08 mg/min with each subsequent infusionMaximum infusion rate (weight less than 30 kg): 0.25 mg/minuteMinimum infusion duration (weight 30 kg or greater): 1.5 hours (based on individual patient tolerability) Comments:-Antipyretics are recommended prior to infusions; anti-histamines should also be given in patients who have had an infusion-associated reaction. -For patients who have had a positive skin test, see dose adjustment section for rechallenge administration. Use: For treatment of patients 2 years or older with confirmed Fabry disease.
Warnings
Many people have a severe reaction to agalsidase beta. Tell your caregiver if you have a skin rash or hives, fever, chills, headache, muscle pain, dizziness, numbness, swelling, vomiting, diarrhea, chest pain, trouble swallowing or breathing, fast or slow heart rate, or severe dizziness.
What other drugs will affect Agalsidase beta
Other drugs may affect agalsidase beta, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions